Cd80 extracellular domain polypeptides and their use in cancer treatment

作者: Barbara Sennino , David Bellovin , Thomas Brennan , David Busha

DOI:

关键词: ChemistryCancer researchDomain (software engineering)CD80CancerExtracellularImmune systemCancer treatmentMolecular biology

摘要: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules their use in treatment of cancer, both alone combination with other therapeutic agents, such as immune stimulating agents PD-1/PD-L1 inhibitors.

参考文章(119)
Lee M. Nadler, Arnold S. Freedman, Gordon J. Freeman, Polypeptides comprising a B7 extracellular domain ,(1995)
Alexandra Lazetic, Juha Punnonen, Steven R. Leong, Chia-Chun Chang, Variant B7 co-stimulatory molecules ,(2001)
Lee M. Nadler, Francescopaolo Borriello, Arlene H. Sharpe, Gordon J. Freeman, Nucleic acid molecules encoding B7-1 ,(2006)
Randal R. Ketchem, Courtney Beers, Jason C. O'neill, Ian Nevin Foltz, Julia C. Piasecki, Gitr antigen binding proteins ,(2014)
Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Paul Michael Scola, Nishith Sanghvi, Li-Qiang Sun, Kenneth M. Boy, Martin Patrick Allen, David R. Langley, Eric P. Gillis, Michael S. Bowsher, Maude A. Poirier, Patrick C. Reid, Claudio Mapelli, Michael Matthew Miller, Eric Mull, Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions ,(2014)
S. Vessillier, D. Eastwood, B. Fox, J. Sathish, S. Sethu, T. Dougall, S.J. Thorpe, R. Thorpe, R. Stebbings, Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm. Journal of Immunological Methods. ,vol. 424, pp. 43- 52 ,(2015) , 10.1016/J.JIM.2015.04.020
Solomon Langermann, Simultaneous inhibition of pd-l1/pd-l2 ,(2010)